Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation

Contraception

Volumn 74, Issue 2, 2006, Pages 90-99

  Kaunitz, Andrew M ^a   Miller, Paul D ^b   Rice, Valerie Montgomery ^c   Ross, Doug ^d   McClung, Michael R ^e  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b University of Colorado Health Sciences Center   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

^d Pfizer Global Pharmaceuticals   (United States)

^e OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Body weight; Bone mineral density; Depo Provera ; DMPA; Lipids

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BODY WEIGHT; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; DRUG WITHDRAWAL; EVALUATION; FEMALE; FOLLOW UP; HIP; HORMONAL CONTRACEPTION; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY; LUMBAR SPINE; MAJOR CLINICAL STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT DURATION; WEIGHT GAIN;

ADULT; BODY WEIGHT; BONE AND BONES; BONE DENSITY; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PROSPECTIVE STUDIES;

EID: 33746261327     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.010     Document Type: Article

References (54)

1. Depo-Provera [physician information] (2004), Pfizer Inc., New York
2. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera®): a highly effective contraceptive option with proven long-term safety. Contraception 68 (2003) 75-87
3. Schwallie P.C., and Assenzo J.R. Contraceptive use - efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 24 (1973) 331-339
4. Piccinino L.J., and Mosher W.D. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 30 (1998) 4-10
5. Banks E., Berrington A., and Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG 108 (2001) 1214-1221
6. Berenson A.B., Breitkopf C.R., Grady J.J., Rickert V.I., and Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103 (2004) 899-906
7. Lara-Torre E., Edwards C.P., Perlman S., and Hertweck S.P. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17 (2004) 17-21
8. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13 (2002) 581-587
9. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159 (2005) 139-144
10. Petitti D.B., Piaggio G., Mehta S., Cravioto M.C., and Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 95 (2000) 736-744
11. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49 (1998) 615-618
12. Cundy T., Cornish J., Roberts H., Elder H., and Reid I.R. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92 (1998) 569-573
13. Gbolade B., Ellis S., Murby B., Randall S., and Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 105 (1998) 790-794
14. Paiva L.C., Pinto-Neto A.M., and Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 58 (1998) 351-355
15. Perrotti M., Bahamondes L., Petta C., and Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril 76 (2001) 469-473
16. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 69 (2004) 99-104
17. Ryan P.J., Singh S.P., and Guillebaud J. Depot medroxyprogesterone and bone mineral density. J Fam Plann Reprod Health Care 28 (2002) 12-15
18. Clark M.K., Sowers M.F.R., Nichols S., and Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 82 (2004) 1580-1586
19. Kalkwarf H.J., and Specker B.L. Bone mineral loss during lactation and recovery after weaning. Obstet Gynecol 86 (1995) 26-32
20. Polatti F., Capuzzo E., Viazzo F., Colleoni R., and Klersy C. Bone mineral changes during and after lactation. Obstet Gynecol 94 (1999) 52-56
21. Hayslip C.C., Klein T.A., Wray H.L., and Duncan W.E. The effects of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 73 (1989) 588-592
22. Paton L.M., Alexander J.L., Nowson C.A., Frame M.G., Kaymakci B., and Wark J.D. Pregnancy and lactation have no long-term deleterious effect on measures of bone mineral in healthy women: a twin study. Am J Clin Nutr 77 (2003) 707-714
23. Kojima N., Douchi T., Kosha S., and Nagata Y. Cross-sectional study of the effects of parturition and lactation on bone mineral density later in life. Maturitas 41 (2002) 203-209
24. Henderson III P.H., Sowers M.F., Kutzko K.E., and Jannausch M.L. Bone mineral density in grand multiparous women with extended lactation. Am J Obstet Gynecol 182 (2000) 1371-1377
25. Chantry C.J., Auinger P., and Byrd R.S. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 158 (2004) 650-656
26. Carranza-Lira S., and Mera J.P. Influence of number of pregnancies and total breast-feeding time on bone mineral density. Int J Fertil 47 (2002) 169-171
27. Kalkwarf H.J., and Specker B.L. Bone mineral changes during pregnancy and lactation. Endocrine 17 (2002) 49-53
28. Michaelsson K., Baron J.A., Farahmand B.Y., and Ljunghall S. Influence of parity and lactation on hip fracture risk. Am J Epidemiol 153 (2001) 1166-1172
29. Kalkwarf H.J. Hormonal and dietary regulation of changes in bone density during lactation and after weaning in women. J Mammary Gland Biol Neoplasia 4 (1999) 319-329
30. Honda A., Kurabayashi T., Yahata T., Tomita M., Takakuwa K., and Tanaka K. Lumbar bone mineral density changes during pregnancy and lactation. Int J Gynaecol Obstet 63 (1998) 253-258
31. Kaunitz A.M. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am 27 (2000) 741-780
32. Cundy T., Ames R., Horne A., Roberts H., Gamble G., and Reid I.R. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 88 (2003) 78-81
33. Cromer B.A., Lazebnik R., Rome E., Bonny A., Ziegler J., and Debanne S.M. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 192 (2005) 42-47
34. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
35. Hui S.L., Slemenda C.W., and Johnston Jr. C.C. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81 (1988) 1804-1809
36. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., and Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 (2001) 989-995
37. Templeman C., Boyd H., and Hertweck S.P. Depomedroxyprogesterone acetate use and weight gain among adolescents. J Pediatr Adolesc Gynecol 13 (2000) 45-46
38. Moore L.L., Valuck R., McDougall C., and Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52 (1995) 215-220
39. Espey E., Steinhart J., Ogburn T., and Qualls C. Depo-Provera associated with weight gain in Navajo women. Contraception 62 (2000) 55-58
40. Mangan S.A., Larsen P.G., and Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 15 (2002) 79-82
41. Danli S., Qingxiang S., and Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception 62 (2000) 15-18
42. Risser W.L., Gefter L.R., Barratt M.S., and Risser J.M.H. Weight change in adolescents who used hormonal contraception. J Adolesc Health 24 (1999) 433-436
43. Pelkman C.L., Chow M., Heinbach R.A., and Rolls B.J. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 73 (2001) 19-26
44. Deslypere J.P., Thiery M., and Vermeulen A. Effect of long-term hormonal contraception on plasma lipids. Contraception 31 (1985) 633-642
45. Fajumi J.O. Alterations in blood lipids and side effects induced by Depo-Provera in Nigerian women. Contraception 27 (1983) 161-175
46. Liew D.F.M., Ng C.S.A., Yong Y.M., and Ratnam S.S. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31 (1985) 51-64
47. Enk L., Landgren B.-M., Lindberg U.-B., Silfverstolpe G., and Crona N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 24 (1992) 85-89
48. Fahmy K., Khairy M., Allam G., Gobran F., and Alloush M. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 44 (1991) 431-444
49. Garza-Flores J., De la Cruz D.L., Valles de Bourges V., Martinez M., Fuziwara J.L., and Perez-Palacios G. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44 (1991) 61-71
50. Kremer J., de Bruijn H.W.A., and Hindriks F.R. Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate. Contraception 22 (1980) 359-367
51. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 57 (1998) 315-324
52. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 349 (1997) 1202-1209
53. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 346 (1995) 1575-1582
54. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. The use of hormonal contraception in women with coexisting medical conditions. Int J Gynaecol Obstet 75 (2001) 93-106